[OH:1][C:2]([C:4](F)(F)F)=[O:3].O[C:9](C(F)(F)F)=O.[NH2:15][C:16]1[C:21]([C:22]2[CH:30]=[CH:29][C:25]([C:26](O)=[O:27])=[C:24]([F:31])[CH:23]=2)=[CH:20][C:19]([C@H:32]2[CH2:36][C@@H](C(OC)=O)[NH:34][CH2:33]2)=[CH:18][N:17]=1.CN(C(ON1N=NC2C=CC=NC1=2)=[N+](C)C)C.F[P-](F)(F)(F)(F)F.CCN(C(C)C)C(C)C.[NH2:74][C@@H:75]([C:78]1[CH:83]=[CH:82][CH:81]=[C:80]([Cl:84])[CH:79]=1)[CH2:76][OH:77]>CN(C=O)C>[NH2:15][C:16]1[N:17]=[CH:18][C:19]([C@@H:32]2[CH2:33][NH:34][C@H:4]([C:2]([O:1][CH3:9])=[O:3])[CH2:36]2)=[CH:20][C:21]=1[C:22]1[CH:30]=[CH:29][C:25]([C:26](=[O:27])[NH:74][C@@H:75]([C:78]2[CH:83]=[CH:82][CH:81]=[C:80]([Cl:84])[CH:79]=2)[CH2:76][OH:77])=[C:24]([F:31])[CH:23]=1A mixture of 4-(2-amino-5-((3R,5S)-5-(methoxycarbonyl)pyrrolidin-3-yl)pyridin-3-yl)-2-fluorobenzoic acid-2TFA (35 mg, 0.060 mmol), HATU (34 mg, 0.089 mmol), and DIEA (0.104 mL, 0.596 mmol) in DMF (2 mL) was treated with (S)-2-amino-2-(3-chlorophenyl)ethanol (51 mg, 0.348 mmol). At completion, the reaction was washed with water and brine, then dried over MgSO4 and concentrated. The crude material was purified by reverse phase prep HPLC to provide (2S,4R)-methyl 4-(6-amino-5-(4-(((S)-1-(3-chlorophenyl)-2-hydroxyethyl)carbamoyl)-3-fluorophenyl)pyridin-3-yl)pyrrolidine-2-carboxylate (4.2 mg, 9%). LCMS (m/z): 513.2, 515.2 (MH+), 0.58 min; 1H NMR (400 MHz, CD3OD) δ ppm 7.97-7.86 (m, 3H), 7.49-7.40 (m, 3H), 7.39-7.34 (m, 2H), 7.33-7.26 (m, 1H), 5.19 (t, J=5.87 Hz, 1H), 4.62 (dd, J=7.63, 10.76 Hz, 1H), 3.93-3.77 (m, 6H), 3.74-3.61 (m, 1H), 2.87 (td, J=6.90, 13.21 Hz, 1H), 2.33-2.21 (m, 1H).
読み込み中…